Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05783609 · ClinicalTrials.gov registry record · Phase 2
Epcoritamab and Rituximab for First-line Follicular Lymphoma
A Phase 2 study of Follicular Lymphoma and Low Grade Non-Hodgkin's Lymphoma, Adult, sponsored by Reid Merryman, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 5
- Study locations
NCT05783609 is a Phase 2 study of Follicular Lymphoma and Low Grade Non-Hodgkin's Lymphoma, Adult that is actively recruiting participants, run by Reid Merryman, MD. The registered enrollment target is 100 participants, below the 134-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (25% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT05783609, a Phase 2 study of Follicular Lymphoma and Low Grade Non-Hodgkin's Lymphoma, Adult, is actively recruiting participants, sponsored by Reid Merryman, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: * Rituximab (a type of monoclonal antibody therapy) * Epcoritamab (a T-cell bispecific antibody)
Conditions Studied
Interventions
- DRUG Epcoritamab
- DRUG Rituximab
Study Locations (5)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
New York
- University of Rochester Medical Center - Rochester
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-06-21 |
| Est. Completion | 2030-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05783609
The ClinicalTrials.gov registry entry for NCT05783609 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 134-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (25% lower). The listed sponsor is Reid Merryman, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Follicular Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Epcoritamab is the first listed.
NCT05783609 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT05783609 about?
NCT05783609 is a clinical study titled "Epcoritamab and Rituximab for First-line Follicular Lymphoma". The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: * Rituximab (a...
What is the current status of trial NCT05783609?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2023-06-21. Estimated completion is 2030-02.
What conditions does trial NCT05783609 study?
This clinical trial studies the following conditions: Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult.
What interventions are being tested in trial NCT05783609?
The interventions under investigation include: Epcoritamab (DRUG), Rituximab (DRUG).
Who is sponsoring clinical trial NCT05783609?
This trial is sponsored by Reid Merryman, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05783609 being conducted?
This trial has 5 study locations across Massachusetts, New York, Ohio, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
Explore more on PlainTrial
Follicular Lymphoma
All registered trials for this condition
Low Grade Non-Hodgkin's Lymphoma, Adult
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.